Stockreport

Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint

CELGENE  (CELG) 
Last celgene earnings: 10/31 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celgene.com
PDF A significantly greater proportion of patients achieved Scalp Physician’s Global Assessment (ScPGA) response at week 16 with OTEZLA compared with placebo [Read more]